<sentence id="0">Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt 's lymphoma .</sentence>
<sentence id="1">Epstein-Barr virus (EBV)-infected cells <scope type="spec" id="0"> <cue type="spec" id="0">may</cue> sustain three distinct forms of virus latency</scope> .</sentence>
<sentence id="2">In lymphoblastoid cell lines , six EBV-encoded nuclear antigens ( EBNA1 , 2 , 3A , 3B , 3C , -LP ) , three latent membrane proteins ( LMP1 , 2A , 2B ) , and two nuclear RNAs ( EBERs ) are expressed .</sentence>
<sentence id="3">This form of latency , termed latency III , is also encountered in some posttransplant lymphoproliferative disorders .</sentence>
<sentence id="4">In EBV-positive cases of Hodgkin 's disease , the EBERs , EBNA1 , and the LMPs are expressed ( latency II ) , whereas in Burkitt 's lymphoma ( BL ) only the EBERs and EBNA1 have been detected ( latency I ) .</sentence>
<sentence id="5">We have studied the expression of EBV proteins in 17 cases of EBV-positive endemic BL by immunohistology .</sentence>
<sentence id="6">Expression of LMP1 was seen in variable proportions of tumor cells in two cases and EBNA2 was detected in some tumor cells in three other cases .</sentence>
<sentence id="7">Also , the BZLF1 trans-activator protein was expressed in a few tumor cells in 6 cases , <scope type="spec" id="1"> <cue type="spec" id="1">indicating</cue> entry into the lytic cycle</scope> .</sentence>
<sentence id="8">A phenotypic drift from latency I to latency III has been observed previously in some BL cell lines .</sentence>
<sentence id="9">Our results <scope type="spec" id="3"> <cue type="spec" id="3">suggest</cue> that a similar phenomenon <scope type="spec" id="4"> <cue type="spec" id="4">may</cue> occur in BL in vivo</scope></scope> and <scope type="spec" id="5"> <cue type="spec" id="5">indicate that</cue> <scope type="neg" id="2">the operational definition of EBV latencies is <cue type="neg" id="2">not</cue> easily applied to human tumors</scope></scope> .</sentence>